# Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis

> **NCT00172003** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Renal Cell Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00172003
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00172003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00172003, "Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00172003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*